HOMe_aFers_1: A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

Sponsor

Universität des Saarlandes (Other)

Overall Status

Completed

CT.gov ID

NCT02905539

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine to what extend a treatment with the iron compounds Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study the potential clinical impact of hypophosphatemia.

Condition or Disease	Intervention/Treatment	Phase
Anemia, Iron-Deficiency	Drug: Iron Isomaltoside 1000 Drug: Ferric Carboxymaltose	Phase 4

Detailed Description

Recent studies suggested that intravenous iron preparations for anemia treatment may have adverse effects on phosphorus regulation, as they may induce an increase in the phosphaturic hormone Fibroblast Growth Factor-23 (FGF-23) and a subsequent fall in plasma phosphorus levels.

So far it is unknown if these effects are class- or substance-specific.

This study will address the question whether among female participants with iron deficiency anemia the application of ferric-(III)-derisomaltose and ferric carboxymaltose will cause episodes of hypophosphatemia to same extend. The investigators will additionally compare the effects of the two iron preparations on other parameters of calcium-phosphate metabolism, and decipher potential consequences of hypophosphatemia by analysing cardiac function, immunological parameters and quality of life.

In order to investigate these outcomes, 60 women with iron deficient anemia will be randomised to receive either ferric-(III)-derisomaltose or ferric carboxymaltose.

The monocentric study will be conducted at Saarland University Medical Center. For each participating woman, the study comprises five visits to the study center during a period of five weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

26 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia

Study Start Date :

Jul 1, 2016

Actual Primary Completion Date :

Jun 1, 2020

Actual Study Completion Date :

Jun 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Iron Isomaltoside 1000 Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.	Drug: Iron Isomaltoside 1000 Other Names: Monofer
Active Comparator: Ferric Carboxymaltose Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.	Drug: Ferric Carboxymaltose Other Names: Ferinject

Arm

Intervention/Treatment

Experimental: Iron Isomaltoside 1000

Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.

Drug: Iron Isomaltoside 1000

Other Names:

Monofer

Active Comparator: Ferric Carboxymaltose

Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.

Drug: Ferric Carboxymaltose

Other Names:

Ferinject

Outcome Measures

Primary Outcome Measures

Incidence of hypophosphatemia [From baseline to day 35]
The incidence of hypophosphatemia is defined as a drop of serum phosphate below 2.0 mg/dl.

Secondary Outcome Measures

Changes of plasma phosphate concentrations. [From baseline to day 35]
Changes of fractional Phosphate urinary excretion. [From baseline to day 35]
Changes of Plasma Vitamin D (active, inactive). [From baseline to day 35]
Changes of fibroblast growth factor 23 (intact and c-terminal). [From baseline to day 35]
Changes of parathyroid Hormone. [From baseline to day 35]
Changes of Plasma calcium. [From baseline to day 35]
Changes of Plasma alkaline Phosphatase. [From baseline to day 35]
Changes of Plasma soluble Klotho. [From baseline to day 35]
Changes of Plasma Hepcidin-25. [From baseline to day 35]
Changes of Serum N-Terminal Propeptide of Type I Collagen (PINP). [From baseline to day 35]
Changes of Pyridinoline (PYD) in the urine [From baseline to day 35]
Changes of Quality of life. [From baseline to day 35]
German Version of the Short Form (36) Health Survey by Matthias Morfeld, Inge Kirchberger, Monika Bullinger.
Incidence of (supra)ventricular cardiac arrhythmias in the ambulatory Electrocardiography. [Before and 7 days after administration of iron compound]
Changes of QT-time in the 12-lead Electrocardiography. [From baseline to day 35]
Changes of QT-Dispersion in the 12-lead Electrocardiography. [From baseline to day 35]
Changes of Left Ventricular Mass Index [From baseline to day 7]
Echocardiographic measurement
Count of monocyte subpopulations. [Right before the singular infusion of the iron compound is started and right after infusion of the iron compound is completed.]
Count of classical , intermediate and nonclassical monocytes using flow cytometry.
Measurement of phagocytic capacity of monocytes. [Right before the singular infusion of the iron compound is started and right after the infusion of iron compound is completed.]
Exposition of Monocytes to Fluoresbrite Yellow Green (YG) Carboxylate Microspheres and subsequent flow cytometric count of Fluorescein isothiocyanate-positive Monocytes.
Changes of fatigue [From baseline to day 35]
The German Version of the Multidimensional Fatigue Inventory. (Smets E. M. A., Garssen B., Bonke B. and Haes de J. C. J. M. (1995). The Multidimensional Fatigue Inventory (MFI); Psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research, 39, 315-325.)
Changes of Left Atrial Volume Index [From Baseline to day 7]
Echocardiographic measurement
Changes of Systolic Ejection Fraction [From Baseline to day 7]
Echocardiographic measurement
Changes of Diastolic Left Ventricular Function [From Baseline to day 7]
Echocardiographic measurement

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

written informed consent,
female,
gynecological blood losses,
age ≥ 18 years,
iron deficiency anemia,
Hemoglobin < 12,0 g/dl,
Serum-Ferritin ≤ 100 ng/ml or Serum-Ferritin ≤ 300 ng/ml and Transferrin-saturation ≤ 30 %,
Intolerance to or inefficacy of an oral iron supplement
estimated Glomerular Filtration Rate > 15 ml/min/1.73 m²

Exclusion Criteria:

known hypersensitivity to MonoFer® or FERINJECT®,
severe, known hypersensitivity to other intravenous iron preparations,
Plasma Phosphate < 2.5 mg/dl at screening,
Hemochromatosis,
Untreated hyperparathyroidism,
Renal replacement therapy/kidney transplantation,
Active malignant disease, disease-free survival for less than 5 years,
Intravenous iron administration within the last 30 days,
Treatment with erythropoietin or erythropoietin-stimulating agents, transfusion of red blood cells, radiotherapy or chemotherapy within the last 60 days,
Surgery under anesthetic within the last 10 days,
Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 fold above levels in healthy individuals,
Acute febrile infections within the last 7 days,
Chronic inflammatory diseases requiring a systemic antiinflammatory treatment,
self-reported severe asthma or eczema,
presence of relative contraindications (any allergy, any immunologic or inflammatory disease, history of atopic allergies), for which a treatment with the medicinal investigational products is not deemed indicated by the investigator,
pregnancy,
women of childbearing potential without an effective method of contraception,
lactating women,
Present alcohol or drug dependency,
Patients with a history of a psychological illness or seizures,
Non-compliance or administration of any investigational drug within 30 days preceding the study start.